Morgan Stanley
EVMN icon

Morgan Stanley’s Evommune Inc EVMN Stock Holding History

Morgan Stanley’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
290,174
+265,104
+1,057% +$6.16M ﹤0.01% 4407
2026
Q1 		$576K Buy
25,070
+16,724
+200% +$378K ﹤0.01% 5421
2025
Q4 		$143K Buy
+8,346
New +$157K ﹤0.01% 6056

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Morgan Stanley's EVMN Position: Q2 2026 in Review

Morgan Stanley increased its Evommune Inc (EVMN) stake by 1,057% in Q2 2026, buying an estimated $6.16M and bringing the position to 290,174 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #4407.

Morgan Stanley first reported a position in EVMN in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Morgan Stanley held 290,174 shares of Evommune Inc worth $3.86M as of Q2 2026.
  • Morgan Stanley bought 265,104 Evommune Inc shares in Q2 2026, an estimated $6.16M.
  • Evommune Inc made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4407 holding.
  • Morgan Stanley first reported a position in Evommune Inc in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.